Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

FDA Okays Novel Use Of Avastin For Treating Metastatic Colorectal Cancers

Genentech, a member of the Roche Group (RHHBY.PK), announced Wednesday that the U.S. Food and Drug Administration or FDA has approved the use of Avastin in combination with fluoropyrimidine-based irinotecan or oxaliplatin chemotherapy, for the treatment of people ailing from metastatic colorectal cancer or mCRC.

Commenting on the approval, Hal Barron, chief medical officer and head of Global Product Development stated, "These people now have the option to continue with Avastin, plus a new chemotherapy after their cancer worsens, which may help them live longer than changing to the new chemotherapy alone."

The company said that Avastin was the only biologic medicine approved by the FDA for the treatment of people with mCRC in combination with intravenous 5FU-based chemotherapy as an initial treatment, as treatment for people whose cancer worsened after chemotherapy alone, and now as a treatment for people whose cancer has worsened after initial treatment with an Avastin-based regimen.

Avastin which exhibited positive results from its Phase III ML18147 study, presented at the American Society of Clinical Oncology, reduced death risk by 19 percent with the median overall survival at 11.2 months compared with 9.8 months for patients who did not receive Avastin in combination with their chemotherapy procedures, said Genentech in a statement.

Also, Avastin reduced progression free survival or PFS-the risk of the cancer worsening or death progression-by 32 percent, with median PFS at 5.7 months compared to 4.1 months in the Avastin free treatment methodology.

Register
To receive FREE breaking news email alerts for Roche Holding AG and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Consumers spent less in July than in the previous month, a surprise retreat that complicates the prevailing belief that the U.S. economic situation is improving. Along with the unexpected drop in spending, government figures released on Friday showed that incomes rose at a slower pace in July than in the previous month. Meanwhile, data on prices indicated that inflation pressures remain tame. India's economy grew faster-than-expected in the three months to June and at the strongest pace in two years, preliminary figures from the Central Statistics Office revealed Friday. Gross domestic product grew 5.7 percent in the April to June quarter, which exceeded economists' forecast for 5.5 percent expansion. The economy grew 4.6 percent in the previous three months. Eurozone inflation slowed as expected in August on falling energy prices giving room for the central bank to support demand and economic recovery without stoking inflation and help the region to create more jobs. The unemployment rate remained unchanged at an elevated level in July. Nonetheless, it was at the lowest since September 2012.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.